Abstract: The present disclosure relates to methods using CRISPR-Cas13a enzyme, complexed with HIV or HCV crRNAs to specifically and sensitively detect and quantify the presence of HIV or HCV RNA in a sample. These methods can be used to diagnose HIV or HCV infection, quantify the concentration of HIV or HCV RNA present in a sample, identify the presence of different HIV or HCV splice variants, subtypes, or mutations, and to monitor reactivation of HIV or HCV transcription.

Abstract: Provided herein are compositions and methods to identify mutations in one or more SARS-CoV-2 structural proteins that affect infectivity.

Abstract: Droplet detection of RNA enables quantification of the absolute amount of target RNA as well as identification of different variant or mutant RNA species. As described herein. RNA detection with high sensitivity and multiplexed specificity can be achieved with short detection times by encapsulating the Cas reaction in droplets and monitoring enzyme kinetics fluorescently.

Abstract: Provided herein are methods and compositions useful for identifying compounds that can inhibit SARS-CoV-2 infection or the effects thereof, especially in cardiomyocytes (CMs), which are highly infectible by SARS-CoV-2 corona viruses.

Abstract: Provided herein is a novel cloning system with rational fragment design and single-pot ligation (pGLUE) that allows systematic exchange and mutagenesis of genes and rapid construction of entire molecular clones and replicons of virus within days.

Abstract: The present invention relates to a process for preparing a composition for washing keratin materials, in particular human keratin fibres such as the hair, comprising the mixing of an anhydrous solid composition comprising one or more anionic surfactants and one or more amphoteric or zwitterionic surfactants with water, followed by agitation and then leaving to stand the aqueous composition obtained from this mixing.

Abstract: The present invention relates to an anhydrous solid composition comprising one or more anionic surfactants, one or more amphoteric or zwitterionic surfactants and one or more C8-C32 fatty acid salts. The invention also relates to a method for the preparation of an aqueous composition for washing, and optionally in addition conditioning, keratin fibres starting from the anhydrous solid composition according to the invention, to the use of an anhydrous solid composition according to the invention for washing, and optionally in addition conditioning, keratin fibres, and also to a kit for the preparation of the aqueous composition for washing, and optionally in addition conditioning, keratin fibres.

Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus and/or reducing transcription of HIV integrated into the genome of an HIV-infected cell. The present disclosure provides compositions and methods for treating an immunodeficiency virus infection.

Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus. The present disclosure provides compositions and methods for treating an immunodeficiency virus infection.

Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus and/or reducing transcription of HIV integrated into the genome of an HIV-infected cell. The present disclosure provides compositions and methods for treating an immunodeficiency virus infection.

Abstract: The present disclosure relates to methods using CRISPR-Cas13 enzyme, complexed with SARS-CoV-2 crRNA guide RNAs to detect and quantify the presence of SARS-CoV-2 RNA in a sample with enhanced specificity and sensitivity. These methods can be used to diagnose SARS-CoV-2 infection, quantify the concentration of SARS-CoV-2 RNA present in a sample, identify the presence of different SARS-CoV-2 splice variants, subtypes, or mutations, and to monitor reactivation of SARS-CoV-2 transcription.

Abstract: The present disclosure relates to methods using CRISPR-Cas13a enzyme, complexed with HIV or HCV crRNAs to specifically and sensitively detect and quantify the presence of HIV or HCV RNA in a sample. These methods can be used to diagnose HIV or HCV infection, quantify the concentration of HIV or HCV RNA present in a sample, identify the presence of different HIV or HCV splice variants, subtypes, or mutations, and to monitor reactivation of HIV or HCV transcription.

Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus and/or reducing transcription of HIV integrated into the genome of an HIV-infected cell. The present disclosure provides compositions and methods for treating an immunodeficiency virus infection.

Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus and/or reducing transcription of HIV integrated into the genome of an HIV-infected cell. The present disclosure provides compositions and methods for treating an immunodeficiency virus infection.

Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus and/or reducing transcription of HIV integrated into the genome of an HIV-infected cell. The present disclosure provides compositions and methods for treating an immunodeficiency virus infection.

Abstract: The present disclosure provides methods of treating a flavivirus infection, and compositions for use in the methods.

Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus and/or reducing transcription of HIV integrated into the genome of an HIV-infected cell. The present disclosure provides compositions and methods for treating an immunodeficiency virus infection.

Abstract: The present disclosure provides methods of treating a flavivirus infection, and compositions for use in the methods.

Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency vims. The methods generally involve contacting an HIV-infected cell in which HIV is latent with an agent that binds a bromodomain (BRD) in the cell. Latently infected cells contain replication-competent integrated HIV-1 genomes that are blocked at the transcriptional level, resulting in the absence of viral protein expression. The present disclosure provides methods for reducing the reservoir of latent immunodeficiency virus in an individual.

Abstract: The present invention provides methods of treating hepatitis C virus (HCV) infection; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from HCV infection. Also provided are methods of treating liver steatosis and liver fibrosis.